SK Capital is facing sustained pressure across its portfolio, as a prolonged downturn in the global chemicals industry drives multiple restructurings, defaults, and strategic repositioning across its holdings, according to a report by Bloomberg.
The $10bn firm, which specialises in chemicals, has seen several of its portfolio companies fall into financial distress in recent years, including the Swiss textile and paper chemicals group Archroma, which recently secured a last-minute extension on roughly $1bn of high-yield debt following protracted negotiations with creditors.
The firm has also been involved in multiple restructurings across its portfolio, with four companies transferred to creditors in recent years and another currently undergoing insolvency proceedings or creditor negotiations. These developments reflect growing strain across parts of the specialty chemicals sector following a sharp and sustained downturn.
The industry disruption has been attributed to a combination of factors, including surging energy costs following the war in Ukraine and intensified global competition, particularly from lower-cost chemical exports from China. These pressures have contributed to margin compression and liquidity challenges across several industrial subsectors.
Archroma’s restructuring highlights the broader stress, with creditors only agreeing to extend maturities after repeated delays and improved terms. In some cases, additional support has come from equity-linked investors and preferred shareholders providing liquidity to stabilise capital structures.
Other SK Capital-backed businesses have also encountered severe difficulties, including prior bankruptcies and asset handovers in the US and Europe. Companies in sectors such as petrochemicals, pigments, and industrial additives have been particularly affected, reflecting cyclical weakness combined with structural overcapacity in global markets.
Performance data from investor filings indicates significant dispersion across SK Capital’s fund vintages, with earlier funds underperforming broader market benchmarks, while more recent vehicles have delivered stronger returns following a shift toward more diversified investments.
The firm, founded in 2007 by industry specialists with deep experience in chemical engineering and industrial investing, initially built its strategy around acquiring non-core assets from larger chemical groups and repositioning them as standalone businesses. Early successes included wastewater treatment chemicals producer Calabrian, later sold to Ineos.
However, since 2022, a series of shocks—including plant disruptions, rising input costs, and global oversupply—have triggered a wave of stress across the sector, exposing the risks of concentrated exposure to cyclical industrial markets.
European holdings have been particularly affected, with energy price volatility and supply chain disruptions compounding weaker demand conditions. Some joint ventures and acquired businesses have struggled to integrate or maintain profitability in this environment.
The firm has increasingly moved to diversify into more defensive sectors such as pharmaceuticals, aerospace, and life sciences, reflecting a broader industry trend toward reducing exposure to highly cyclical industrial segments.
Recent investments include healthcare and specialty industrial businesses, alongside selective exits where possible. Despite ongoing challenges, parts of the chemicals market in Europe have shown early signs of stabilisation, supported by improved margins and shifting trade flows linked to geopolitical disruptions.
However, analysts caution that any recovery may be short-lived, with potential for renewed volatility if supply-demand imbalances re-emerge once current market disruptions normalise.
